Profile data is unavailable for this security.
About the company
InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal T cell function. The Company conducts its businesses in domestic and overseas markets.
- Revenue in CNY (TTM)1.43bn
- Net income in CNY-229.64m
- Incorporated2015
- Employees1.15k
- LocationInnoCare Pharma LtdBuilding 8, No. 8Life Science Park Road, ZhongguancunLife Science Park, Changping DistrictBeijing 102206ChinaCHN
- Phone+86 1 066609913
- Fax+86 1 060702992
- Websitehttps://www.innocarepharma.com/
More ▼
Mergers & acquisitions
| Acquired company | 688428:SHH since announced | Transaction value |
|---|---|---|
| Guangzhou Innocare Pharma Tech Co Ltd | -23.70% | 65.07m |
Data delayed at least 15 minutes, as of Feb 11 2026.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HitGen Inc | 498.51m | 114.11m | 12.12bn | 483.00 | 107.14 | 8.24 | -- | 24.31 | 0.2824 | 0.2824 | 1.24 | 3.67 | 0.2726 | 6.37 | 4.69 | 1,032,114.00 | 6.18 | 3.06 | 6.87 | 3.36 | 55.23 | 53.55 | 22.67 | 14.48 | 5.12 | 6.59 | 0.1674 | 34.32 | 14.99 | 10.08 | 26.13 | -15.65 | 3.16 | -- |
| InventisBio Co Ltd | 180.53m | -116.28m | 13.55bn | 185.00 | -- | 8.14 | -- | 75.06 | -0.2012 | -0.2012 | 0.3122 | 2.88 | 0.0988 | -- | 1.03 | 975,824.70 | -6.36 | -32.89 | -6.76 | -35.22 | 99.41 | -- | -64.41 | -682.73 | -- | -- | 0.0127 | -- | -9.02 | 25.00 | 15.41 | -- | -3.97 | -- |
| Mabwell Shanghai Bioscience Co Ltd | 624.52m | -947.49m | 14.80bn | 1.36k | -- | 19.44 | -- | 23.69 | -2.37 | -2.37 | 1.56 | 1.90 | 0.1384 | 0.3458 | 14.57 | 441,048.00 | -21.06 | -29.90 | -36.19 | -36.18 | 88.72 | 85.56 | -152.14 | -1,188.68 | 0.8093 | -10.82 | 0.7353 | -- | 56.28 | 46.68 | 0.9031 | -- | 12.25 | -- |
| Sinocelltech Group Ltd | 1.89bn | -310.15m | 18.08bn | 2.28k | -- | -- | -- | 9.58 | -0.6964 | -0.6964 | 4.24 | -0.1083 | 0.5458 | 0.4325 | 3.04 | 828,989.10 | -8.37 | -22.66 | -29.60 | -48.25 | 93.51 | 95.52 | -15.33 | -42.96 | 0.5008 | -0.6753 | 1.02 | -- | 33.13 | 294.24 | 127.39 | -- | 23.95 | -- |
| BeBetter Med Inc | -100.00bn | -100.00bn | 19.60bn | 150.00 | -- | 91.01 | -- | -- | -- | -- | -- | 0.4785 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0116 | -- | -- | -- | 67.59 | -- | -- | -- |
| InnoCare Pharma Ltd | 1.43bn | -229.64m | 24.19bn | 1.15k | -- | 6.63 | -- | 16.95 | -0.1508 | -0.1508 | 0.8855 | 3.78 | 0.1504 | 1.70 | 3.74 | 1,245,225.00 | -2.52 | -6.41 | -2.87 | -7.45 | 86.97 | 86.07 | -16.78 | -71.71 | 6.44 | -- | 0.1996 | -- | 36.68 | 281.63 | 30.20 | -- | 3.42 | -- |
| Dizal Pharmaceutical Co Ltd | 607.75m | -867.44m | 25.36bn | 852.00 | -- | 17.41 | -- | 41.73 | -2.01 | -2.01 | 1.40 | 3.14 | 0.2644 | 0.8102 | 5.84 | 713,322.50 | -37.97 | -46.55 | -55.30 | -56.24 | 95.12 | 90.63 | -143.64 | -825.75 | 2.42 | -111.09 | 0.4239 | -- | 294.24 | 54.40 | 23.63 | -- | 58.33 | -- |
| Joinn Laboratories China Co Ltd | 1.67bn | 225.09m | 25.93bn | 2.65k | 109.60 | 3.44 | -- | 15.54 | 0.3405 | 0.3405 | 2.37 | 10.84 | 0.175 | 0.7843 | 6.03 | 629,011.80 | 2.36 | 6.60 | 2.72 | 7.92 | 24.63 | 41.87 | 13.47 | 25.98 | 3.06 | -- | 0.0039 | 23.59 | -15.07 | 25.85 | -81.34 | -16.89 | 16.27 | -19.46 |
| Wuhan Healthgen Biotechnology Corp | 23.39m | -160.81m | 26.70bn | 215.00 | -- | 53.73 | -- | 1,141.74 | -0.4498 | -0.4498 | 0.0654 | 1.39 | -- | -- | -- | 131,386.80 | -- | -- | -- | -- | 41.12 | -- | -687.60 | -- | 0.359 | -30.87 | 0.5497 | -- | 3.92 | -- | 19.04 | -- | -- | -- |
| Biocytogen Phrmutcls (Beijing) Co Ltd | 1.33bn | 249.94m | 30.15bn | 1.28k | 134.37 | 34.42 | 77.63 | 22.64 | 0.5593 | 0.5593 | 2.98 | 2.18 | -- | -- | -- | 1,215,939.00 | -- | -- | -- | -- | 76.56 | -- | 18.77 | -- | 1.11 | 14.77 | 0.5281 | -- | 36.76 | -- | 108.76 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to InnoCare Pharma Ltd's reporting currency: Chinese Yuan Renminbi CNY
43.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 20.43m | 7.85% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 17.94m | 6.90% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 14.62m | 5.62% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 13.99m | 5.38% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 13.43m | 5.16% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 10.45m | 4.02% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2025 | 7.34m | 2.82% |
| Ping An Fund Management Co., Ltd.as of 30 Jun 2025 | 5.80m | 2.23% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2025 | 5.32m | 2.05% |
| Baoying Fund Management Co., Ltd.as of 30 Jun 2025 | 4.46m | 1.71% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
